866-997-4948(US-Canada Toll Free)

Therapeutic Nuclear Medicines Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Published By :

Future Market Insights

Published Date : Jan 2019

Category :

Therapeutic Area

No. of Pages : 237 Pages

A recent market study published by FMI – “Therapeutic Nuclear Medicines Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028” consists of a comprehensive assessment of the most important market dynamics. On conducting a thorough research of the historic as well as current growth parameters of the therapeutic nuclear medicines market, the growth prospects are obtained with maximum precision. The therapeutic nuclear medicines market report features the unique and salient factors that are likely to significantly impact the development of the therapeutic nuclear medicines market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the therapeutic nuclear medicines market in the upcoming years. The report provides detailed information about the current and future growth prospects of the therapeutic nuclear medicines market in the most comprehensive manner for the better understanding of readers.

Chapter 1 – Executive Summary

The therapeutic nuclear medicines market report commences with an executive summary of the key findings and key statistics of the therapeutic nuclear medicines market. It also includes the market value (US$ million) estimates of the leading segments of the therapeutic nuclear medicines market.

Chapter 2 – Market Introduction

Readers can find detailed taxonomy and the definition of the therapeutic nuclear medicines market in this chapter, which helps understand the basic information about the therapeutic nuclear medicines. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the therapeutic nuclear medicines market report.

Chapter 3 – Global Economic Outlook

This section highlights the healthcare spending of the top countries in each region. This section also explains the global and regional healthcare market outlook. The regional healthcare market focuses is analysed in depth to assess the political, economic and business environment outlook of the respective region.

Chapter 4 – Market Opportunity Analysis

This chapter explains the key macro-economic factors that are expected to influence the growth of the therapeutic nuclear medicines market over the forecast period. Along with macroeconomic factors, this section also highlights the opportunity analysis for the therapeutic nuclear medicines market. It helps readers understand the market opportunity, based on which they can plan their strategies.

Chapter 5 – Market Dynamics

This chapter highlights the key dynamics of the therapeutic nuclear medicines market, which include the drivers, restraints and trends. The supply-side drivers as well as the demand-side drivers of the therapeutic nuclear medicines market are explained well in this chapter. This chapter is expected to enable readers to understand the factors that are propelling the therapeutic nuclear medicines market, as well as those that are likely to hamper the growth of the therapeutic nuclear medicines market. Moreover, readers will understand the key trends followed by the leading manufacturers in the therapeutic nuclear medicines market.

Chapter 6 – Key Inclusions

This chapter highlights the key inclusions of the therapeutic nuclear medicines market report, which include key regulations, reimbursement scenario and pipeline assessment. The analysis of the parent market helps readers understand the share of the global therapeutic nuclear medicines market in the overall radiopharmaceutical market. The key regulations section of this chapter highlights the FDA and EMA regulatory processes for the approval of drugs. The reimbursement scenario provides the CPT codes used for therapeutic nuclear medicines, as well as the detailed explanation about each CPT code. The pipeline assessment includes the list of clinical trials pertaining to therapeutic nuclear medicines around the globe.

Chapter 7 – North America Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes a detailed analysis of the growth of the North America therapeutic nuclear medicines market along with a country-wise assessment, which includes the U.S. and Canada. Readers can also find the key takeaways of this region, and market growth based on treatment type, disease type, end user and country of therapeutic nuclear medicines in the North America region.

Chapter 8 – Latin America Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter contains a snapshot of the Latin America therapeutic nuclear medicines market. It includes the growth prospects of the therapeutic nuclear medicines market in the leading LATAM countries such as Brazil, Mexico, Argentina and the rest of the Latin America region.

Chapter 9 – Western Europe Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

The important growth prospects of the therapeutic nuclear medicines market based on its radionuclide type, indication and distribution channel in several European countries, such as the U.K., Germany, France, Italy Spain and the rest of Western Europe, is included in this chapter.

Chapter 10 – Eastern Europe Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter highlights the growth of the therapeutic nuclear medicines market in Eastern Europe by focusing on Russia and Poland. This section also helps readers understand the key factors that are responsible for the growth of the therapeutic nuclear medicines market in Eastern Europe.

Chapter 11 – APECJ Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Australia & New Zealand, India and ASEAN are the leading countries in the APECJ region that are the prime subjects of assessment to obtain the growth prospects of the APECJ therapeutic nuclear medicines market in this chapter. Readers can find detailed information about the growth parameters of the APEJ therapeutic nuclear medicines market during the period 2018-2028.

Chapter 12 – China Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

The key factors responsible for the robust growth of the China therapeutic nuclear medicines market is explained in this section. The market analysis by radionuclide type, indication and distribution channel of the therapeutic nuclear medicines market is explained in this section, which provides readers an in-depth analysis of the China therapeutic nuclear medicines market.

Chapter 13 – Japan Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Readers can find important factors that can significantly impact the growth of the therapeutic nuclear medicines market in Japan during the forecast period based on the market segmentation.

Chapter 14 – MEA Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter provides information about the growth of the therapeutic nuclear medicines market in the major countries of the MEA region, such as GCC Countries and South Africa, during the period 2018-2028.

Chapter 15 – Forecast Factors – Relevance and Impact

This chapter highlights the key factors taken into consideration which forecasting the market value of the global therapeutic nuclear medicines market. The impact of this forecast factor in different regions is also mentioned in this chapter.

Chapter 16 – Market Structure Analysis

This section explains the tier structure of the global therapeutic nuclear medicines market, which helps readers understand the percent share of the market based on the tier 1, tier 2 and tier 3 players in the therapeutic nuclear medicines market. This section also explains the company share analysis for the therapeutic nuclear medicines market, which helps readers understand the market share held by the key players of the therapeutic nuclear medicines market.

Chapter 17 – Competition Landscape

In this chapter, readers can find a comprehensive list of all the leading manufacturers in the therapeutic nuclear medicines market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, recent company developments and SWOT analysis.  Some of the players featured in the therapeutic nuclear medicines market report are Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc.

Chapter 18 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Region

This chapter explains how the therapeutic nuclear medicines market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan (APECJ), China, Japan and the Middle East & Africa (MEA).

Chapter 19 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Radionuclide Type

Based on the treatment type, the therapeutic nuclear medicines market is segmented into Radium-223, Iodine-131, Leutitium-177, Yttrium-90, Samarium-153, Strontium-89, Rhenium-188+ Rhenium-186, Erbium-169, Phosphorus-32 and others. In this chapter, readers can find a detailed analysis of the therapeutic nuclear medicines market by different radionuclide types and their expected growth over the forecast period.

Chapter 20 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Indication

Based on the indication, the therapeutic nuclear medicines market is segmented as prostate cancer, painful bone metastases, thyroid cancer, neuroblastoma, synovitis, non-Hodgkins lymphoma, hepatic metastases, brain tumour and others. This section helps readers understand the penetration of different indications in the therapeutic nuclear medicines market over the forecast period.

Chapter 21 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Distribution Channel

Based on the distribution channel, the therapeutic nuclear medicines market is segmented into hospitals, ambulatory surgical centres and cancer research institutes. In this chapter, readers can understand the market attractive analysis based on the distribution channel.

Chapter 22 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment, 2018-2028

This section explain the global market analysis and forecast for the therapeutic nuclear medicines market. It also highlights the incremental opportunity for the therapeutic nuclear medicines market along with the absolute dollar opportunity for every year between the forecast period of 2018-2028. 

Chapter 23 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 24 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions and important qualitative information & quantitative information about the therapeutic nuclear medicines market.

Table of Content

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Exclusion and Inclusion

3. Global Economic Outlook
3.1. Gross Domestic Product by Country, 2006 – 2021
3.2. Global Pharmaceutical Market Overview

4. Market Opportunity Analysis
4.1. Macro-Economic Factors
4.2. Opportunity Analysis

5. Market Dynamics
5.1. Drivers
5.1.1. Supply Side Drivers
5.1.2. Demand Side Drivers
5.2. Restraints
5.3. Trends

6. Key Inclusion
6.1. Parent Market Analysis
6.2. Key Regulation
6.3. Reimbursement Scenario
6.4. Pipeline Assessment
6.5. Disease Epidemiology

7. North America Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
7.4. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
7.4.1. Radium-223
7.4.2. Iodine-131
7.4.3. Leutitium-177
7.4.4. Yttrium-90
7.4.5. Samarium-153
7.4.6. Strontium-89
7.4.7. Rhenium-188 + Rhenium-186
7.4.8. Erbium-169
7.4.9. Phosphorus-32
7.4.10. Others
7.5. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
7.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
7.6.1. Prostate Cancer
7.6.2. Painful Bone Metastases
7.6.3. Thyroid Cancer
7.6.4. Neuroblastoma
7.6.5. Synovitis
7.6.6. Non-Hodgkins Lymphoma
7.6.7. Hepatic Metastases
7.6.8. Brain Tumour
7.6.9. Others
7.7. Market Size (US$ Mn) Forecast By Indication, 2018-2028
7.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
7.8.1. Hospitals
7.8.2. Ambulatory Surgical Centers
7.8.3. Cancer Research Institutes
7.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
7.10. Market Attractiveness Analysis
7.10.1. By Radionuclide Type
7.10.2. By Indication
7.10.3. By End User
7.10.4. By Country
7.11. Drivers and Restraints: Impact Analysis

8. Latin America Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Argentina
8.2.4. Rest of Latin America
8.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
8.4. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
8.4.1. Radium-223
8.4.2. Iodine-131
8.4.3. Leutitium-177
8.4.4. Yttrium-90
8.4.5. Samarium-153
8.4.6. Strontium-89
8.4.7. Rhenium-188 + Rhenium-186
8.4.8. Erbium-169
8.4.9. Phosphorus-32
8.4.10. Others
8.5. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
8.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
8.6.1. Prostate Cancer
8.6.2. Painful Bone Metastases
8.6.3. Thyroid Cancer
8.6.4. Neuroblastoma
8.6.5. Synovitis
8.6.6. Non-Hodgkins Lymphoma
8.6.7. Hepatic Metastases
8.6.8. Brain Tumour
8.6.9. Others
8.7. Market Size (US$ Mn) Forecast By Indication, 2018-2028
8.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
8.8.1. Hospitals
8.8.2. Ambulatory Surgical Centers
8.8.3. Cancer Research Institutes
8.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
8.10. Market Attractiveness Analysis
8.10.1. By Radionuclide Type
8.10.2. By Indication
8.10.3. By End User
8.10.4. By Country
8.11. Drivers and Restraints: Impact Analysis

9. Western Europe Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
9.2.1. Germany
9.2.2. U.K
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Western Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
9.4. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
9.4.1. Radium-223
9.4.2. Iodine-131
9.4.3. Leutitium-177
9.4.4. Yttrium-90
9.4.5. Samarium-153
9.4.6. Strontium-89
9.4.7. Rhenium-188 + Rhenium-186
9.4.8. Erbium-169
9.4.9. Phosphorus-32
9.4.10. Others
9.5. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
9.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
9.6.1. Prostate Cancer
9.6.2. Painful Bone Metastases
9.6.3. Thyroid Cancer
9.6.4. Neuroblastoma
9.6.5. Synovitis
9.6.6. Non-Hodgkins Lymphoma
9.6.7. Hepatic Metastases
9.6.8. Brain Tumour
9.6.9. Others
9.7. Market Size (US$ Mn) Forecast By Indication, 2018-2028
9.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
9.8.1. Hospitals
9.8.2. Ambulatory Surgical Centers
9.8.3. Cancer Research Institutes
9.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
9.10. Market Attractiveness Analysis
9.10.1. By Radionuclide Type
9.10.2. By Indication
9.10.3. By End User
9.10.4. BY Country
9.11. Drivers and Restraints: Impact Analysis

10. Eastern Europe Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
10.2.1. Russia
10.2.2. Poland
10.2.3. Rest of Eastern Europe
10.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
10.4. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
10.4.1. Radium-223
10.4.2. Iodine-131
10.4.3. Leutitium-177
10.4.4. Yttrium-90
10.4.5. Samarium-153
10.4.6. Strontium-89
10.4.7. Rhenium-188 + Rhenium-186
10.4.8. Erbium-169
10.4.9. Phosphorus-32
10.4.10. Others
10.5. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
10.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
10.6.1. Prostate Cancer
10.6.2. Painful Bone Metastases
10.6.3. Thyroid Cancer
10.6.4. Neuroblastoma
10.6.5. Synovitis
10.6.6. Non-Hodgkins Lymphoma
10.6.7. Hepatic Metastases
10.6.8. Brain Tumour
10.6.9. Others
10.7. Market Size (US$ Mn) Forecast By Indication, 2018-2028
10.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
10.8.1. Hospitals
10.8.2. Ambulatory Surgical Centers
10.8.3. Cancer Research Institutes
10.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
10.10.Market Attractiveness Analysis
10.10.1. By Radionuclide Type
10.10.2. By Indication
10.10.3. By End User
10.10.4. By Country
10.11. Drivers and Restraints: Impact Analysis

11. APECJ Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
11.2.1. India
11.2.2. Australia and New Zealand
11.2.3. ASEAN
11.2.4. Rest of APECJ
11.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
11.4. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
11.4.1. Radium-223
11.4.2. Iodine-131
11.4.3. Leutitium-177
11.4.4. Yttrium-90
11.4.5. Samarium-153
11.4.6. Strontium-89
11.4.7. Rhenium-188 + Rhenium-186
11.4.8. Erbium-169
11.4.9. Phosphorus-32
11.4.10. Others
11.5. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
11.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
11.6.1. Prostate Cancer
11.6.2. Painful Bone Metastases
11.6.3. Thyroid Cancer
11.6.4. Neuroblastoma
11.6.5. Synovitis
11.6.6. Non-Hodgkins Lymphoma
11.6.7. Hepatic Metastases
11.6.8. Brain Tumour
11.6.9. Others
11.7. Market Size (US$ Mn) Forecast By Indication, 2018-2028
11.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
11.8.1. Hospitals
11.8.2. Ambulatory Surgical Centers
11.8.3. Cancer Research Institutes
11.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
11.10.Market Attractiveness Analysis
11.10.1. By Radionuclide Type
11.10.2. By Indication
11.10.3. By End User
11.10.4. By Country
11.11. Drivers and Restraints: Impact Analysis

12. China Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
12.2.1. Radium-223
12.2.2. Iodine-131
12.2.3. Leutitium-177
12.2.4. Yttrium-90
12.2.5. Samarium-153
12.2.6. Strontium-89
12.2.7. Rhenium-188 + Rhenium-186
12.2.8. Erbium-169
12.2.9. Phosphorus-32
12.2.10. Others
12.3. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
12.4. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
12.4.1. Prostate Cancer
12.4.2. Painful Bone Metastases
12.4.3. Thyroid Cancer
12.4.4. Neuroblastoma
12.4.5. Synovitis
12.4.6. Non-Hodgkins Lymphoma
12.4.7. Hepatic Metastases
12.4.8. Brain Tumour
12.4.9. Others
12.5. Market Size (US$ Mn) Forecast By Indication, 2018-2028
12.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
12.6.1. Hospitals
12.6.2. Ambulatory Surgical Centers
12.6.3. Cancer Research Institutes
12.7. Market Size (US$ Mn) Forecast By End User, 2018-2028
12.8. Market Attractiveness Analysis
12.8.1. By Radionuclide Type
12.8.2. By Indication
12.8.3. By End User
12.9. Drivers and Restraints: Impact Analysis

13. Japan Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
13.2.1. Radium-223
13.2.2. Iodine-131
13.2.3. Leutitium-177
13.2.4. Yttrium-90
13.2.5. Samarium-153
13.2.6. Strontium-89
13.2.7. Rhenium-188 + Rhenium-186
13.2.8. Erbium-169
13.2.9. Phosphorus-32
13.2.10. Others
13.3. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
13.4. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
13.4.1. Prostate Cancer
13.4.2. Painful Bone Metastases
13.4.3. Thyroid Cancer
13.4.4. Neuroblastoma
13.4.5. Synovitis
13.4.6. Non-Hodgkins Lymphoma
13.4.7. Hepatic Metastases
13.4.8. Brain Tumour
13.4.9. Others
13.5. Market Size (US$ Mn) Forecast By Indication, 2018-2028
13.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
13.6.1. Hospitals
13.6.2. Ambulatory Surgical Centers
13.6.3. Cancer Research Institutes
13.7. Market Size (US$ Mn) Forecast By End User, 2018-2028
13.8. Market Attractiveness Analysis
13.8.1. By Radionuclide Type
13.8.2. By Indication
13.8.3. By End User
13.9. Drivers and Restraints: Impact Analysis

14. MEA Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
14.2.1. GCC Countries
14.2.2. South Africa
14.2.3. Rest of Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
14.4. Historical Market Size (US$ Mn) Trend Analysis By Radionuclide Type, 2013-2017
14.4.1. Radium-223
14.4.2. Iodine-131
14.4.3. Leutitium-177
14.4.4. Yttrium-90
14.4.5. Samarium-153
14.4.6. Strontium-89
14.4.7. Rhenium-188 + Rhenium-186
14.4.8. Erbium-169
14.4.9. Phosphorus-32
14.4.10. Others
14.5. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
14.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
14.6.1. Prostate Cancer
14.6.2. Painful Bone Metastases
14.6.3. Thyroid Cancer
14.6.4. Neuroblastoma
14.6.5. Synovitis
14.6.6. Non-Hodgkins Lymphoma
14.6.7. Hepatic Metastases
14.6.8. Brain Tumour
14.6.9. Others
14.7. Market Size (US$ Mn) Forecast By Indication, 2018-2028
14.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
14.8.1. Hospitals
14.8.2. Ambulatory Surgical Centers
14.8.3. Cancer Research Institutes
14.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
14.10.Market Attractiveness Analysis
14.10.1. By Radionuclide Type
14.10.2. By Indication
14.10.3. By End User
14.10.4. By Country
14.11. Drivers and Restraints: Impact Analysis

15. Forecast Factors: Relevance and Impact

16. Market Structure Analysis

16.1. Market Structure by Tier
16.2. Market Share Analysis (2017) for Top Players, By Region

17. Competition Analysis
17.1. Competition Dashboard
17.2. Competitors Deep Dive
17.2.1. Bayer AG
17.2.2. Novartis AG
17.2.3. GE Healthcare
17.2.4. Curium Pharmaceuticals
17.2.5. Jubilant DraxImage
17.2.6. Spectrum Pharmaceuticals
17.2.7. Progenics Pharmaceuticals, Inc.
17.2.8. ANSTO
17.2.9. Lantheus Medical Imaging, Inc.
17.2.10. Eckert & Ziegler
17.2.11. International Isotopes Inc.
17.2.12. SHINE Medical Technologies Inc.

18. Global Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028 By Country
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Mn) Analysis By Country
18.2.1. North America
18.2.2. Latin America
18.2.3. Western Europe
18.2.4. Eastern Europe
18.2.5. Asia Pacific Excluding Japan And China
18.2.6. China
18.2.7. Japan
18.2.8. Middle East and Africa
18.3. Market Size (US$ Mn) Forecast By Country
18.4. Market Attractiveness Analysis By Country

19. Global Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028, By Radionuclide Type
19.1. Introduction/Key Finding
19.2. Historical Market Size (US$ Mn) Analysis By Radionuclide Type, 2013-2017
19.2.1. Radium-223
19.2.2. Iodine-131
19.2.3. Leutitium-177
19.2.4. Yttrium-90
19.2.5. Samarium-153
19.2.6. Strontium-89
19.2.7. Rhenium-188 + Rhenium-186
19.2.8. Erbium-169
19.2.9. Phosphorus-32
19.2.10. Others
19.3. Market Size (US$ Mn) Forecast By Radionuclide Type, 2018-2028
19.4. Market Attractiveness Analysis By Radionuclide Type

20. Global Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028, By Indication
20.1. Introduction/Key Finding
20.2. Historical Market Size (US$ Mn) Analysis By Indication, 2013-2017
20.2.1. Prostate Cancer
20.2.2. Painful Bone Metastases
20.2.3. Thyroid Cancer
20.2.4. Neuroblastoma
20.2.5. Synovitis
20.2.6. Non-Hodgkins Lymphoma
20.2.7. Hepatic Metastases
20.2.8. Brain Tumour
20.2.9. Others
20.3. Market Size (US$ Mn) Forecast By Indication, 2018-2028
20.4. Market Attractiveness Analysis By Indication

21. Global Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028, By End User
21.1. Introduction/Key Finding
21.2. Historical Market Size (US$ Mn) Analysis By End User, 2013-2017
21.2.1. Hospitals
21.2.2. Ambulatory Surgical Centers
21.2.3. Cancer Research Institutes
21.3. Market Size (US$ Mn) Forecast By End User, 2018-2028
21.4. Market Attractiveness Analysis By End User

22. Global Therapeutic Nuclear Medicine Market Analysis 2013–2017 and Forecast 2018–2028
22.1. Global Market Value Analysis (US$ Mn)
22.2. Absolute $ Opportunity (US$ Mn)

23. Assumptions and Acronyms Used

24. Research Methodology

List of Table

List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 – 2021
Table 02: CPT codes for Therapeutic Nuclear Medicine Procedures
Table 03: Estimated prevalence cases of cancer by country
Table 04: Clinical Trials on Therapeutic Nuclear Medicine (1/5)
Table 05: Clinical Trials on Therapeutic Nuclear Medicine (2/5)
Table 06: Clinical Trials on Therapeutic Nuclear Medicine (3/5)
Table 07: Clinical Trials on Therapeutic Nuclear Medicine (4/5)
Table 08: Clinical Trials on Therapeutic Nuclear Medicine (1/5)
Table 09: North America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Country
Table 10: North America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 11: North America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 12: North America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 13: Latin America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Country
Table 14: Latin America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 15: Latin America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 16: Latin America Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 17: Western Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Country
Table 18: Western Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 19: Western Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 20: Western Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 21: Eastern Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Country
Table 22: Eastern Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 23: Eastern Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 24: Eastern Europe Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 25: APECJ Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Country
Table 26: APECJ Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 27: APECJ Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 28: APECJ Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 29: China Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 30: China Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 31: China Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 32: Japan Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 33: Japan Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 34: Japan Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 35: MEA Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Country
Table 36: MEA Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Radionuclide Type
Table 37: MEA Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By Indication
Table 38: MEA Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018–2028, By End User
Table 39: Global Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis and Opportunity Assessment 2013–2028, By Region
Table 40: Global Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis and Opportunity Assessment 2013–2028, By Radionuclide Type 
Table 41: Global Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis and Opportunity Assessment 2013–2028, By Indication
Table 42: Global Therapeutic Nuclear Medicines Market Value (US$ Mn) Analysis- and Opportunity Assessment 2013–2028, By End User

List of Chart

List of Figures

Figure 01: Global Radiopharmaceuticals Market Overview
Figure 02: North America Therapeutic Nuclear Medicines Market Value Share By Country (2018 E)
Figure 03: North America Therapeutic Nuclear Medicines Market Value Share By Radionuclide Type (2018 E)
Figure 04: North America Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 05: North America Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 06: North America Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 07: North America Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 08: U.S. Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 09: U.S. Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 10: Canada Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 11: Canada Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 12: North America Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 13: North America Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 14: North America Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 15: North America Therapeutic Nuclear Medicines Market Attractiveness Analysis by Country, 2018-2028
Figure 16: Latin America Therapeutic Nuclear Medicines Market Value Share By Country (2018 E)
Figure 17: Latin America Therapeutic Nuclear Medicines Market Value Share By Radionuclide Type (2018 E)
Figure 18: Latin America Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 19: Latin America Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 20: Latin America Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 21: Latin America Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 22: Brazil Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 23: Brazil Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 24: Mexico Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 25: Mexico Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 26: Argentina Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 27: Argentina Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 28: Rest of Latin America Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 29: Rest of Latin America Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 30: Latin America Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 31: Latin America Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 32: Latin America Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 33: Latin America Therapeutic Nuclear Medicines Market Attractiveness Analysis by Country, 2018-2028
Figure 34: Western Europe Therapeutic Nuclear Medicines Market Value Share By Country (2018 E)
Figure 35: Western Europe Therapeutic Nuclear Medicines Market Value Share By Radionuclide Type (2018 E)
Figure 36: Western Europe Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 37: Western Europe Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 38: Western Europe Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 39: Western Europe Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 40: U.K. Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 41: U.K. Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 42: Germany Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 43: Germany Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 44: France Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 45: France Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 46: Italy Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn),  2013-2017
Figure 47: Italy Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 48: Spain Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 49: Spain Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 50: Rest of Western Europe Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 51: Rest of Western Europe Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 52: Western Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 53: Western Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 54: Western Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 55: Western Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by Country, 2018-2028
Figure 56: Eastern Europe Therapeutic Nuclear Medicines Market Value Share By Country (2018 E)
Figure 57: North America Therapeutic Nuclear Medicines Market Value Share By Radionuclide Type (2018 E)
Figure 58: Eastern Europe Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 59: Eastern Europe Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 60: Eastern Europe Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 61: Eastern Europe Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 62: Russia Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 63: Russia Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 64: Poland Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 65: Poland Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 66: Rest of Eastern Europe Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 67: Rest of Eastern Europe Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 68: Eastern Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 69: Eastern Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 70: Eastern Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 71: Eastern Europe Therapeutic Nuclear Medicines Market Attractiveness Analysis by Country, 2018-2028
Figure 72: APECJ Therapeutic Nuclear Medicines Market Value Share By Country (2018 E)
Figure 73: APECJ Therapeutic Nuclear Medicines Market Value Share By Radionuclide Type (2018 E)
Figure 74: APECJ Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 75: APECJ Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 76: APECJ Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 77: APECJ Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 78: India Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 79: India Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 80: Australia & NZ Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 81: Australia & NZ Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 82: ASEAN Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 83: ASEAN Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 84: Rest of APECJ Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 85: Rest of APECJ Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 86: APECJ Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 87: APECJ Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 88: APECJ Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 89: APECJ Therapeutic Nuclear Medicines Market Attractiveness Analysis by Country, 2018-2028
Figure 90: China Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 91: China Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 92: China Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 93: China Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 94: China Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 95: China Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 96: China Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 97: China Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 98: Japan Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 99: Japan Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 100: Japan Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 101: Japan Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 102: Japan Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 103: Japan Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 104: Japan Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 105: Japan Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 106: MEA Therapeutic Nuclear Medicines Market Value Share By Country (2018 E)
Figure 107: MEA Therapeutic Nuclear Medicines Market Value Share By Radionuclide Type (2018 E)
Figure 108: MEA Therapeutic Nuclear Medicines Market Value Share Indication (2018 E)
Figure 109: MEA Therapeutic Nuclear Medicines Market Value Share By End User (2018 E)
Figure 110: MEA Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 111: MEA Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 112: South Africa Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 113: South Africa Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 114: GCC Countries Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 115: GCC Countries Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 116: Rest of MEA Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 117: Rest of MEA Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 118: MEA Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 119: MEA Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 120: MEA Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 121: MEA Therapeutic Nuclear Medicines Market Attractiveness Analysis by Country, 2018-2028
Figure 123: Global Therapeutic Nuclear Medicines Market: Company Share Analysis (2017)
Figure 124: Global Therapeutic Nuclear Medicines Market Share Analysis (%), By Region, 2018 & 2028
Figure 125: Global Therapeutic Nuclear Medicines Market Y-o-Y Analysis (%), By Region, 2018-2028
Figure 126: Global Therapeutic Nuclear Medicines Market Attractiveness Analysis by Region, 2018-2028
Figure 127: Global Therapeutic Nuclear Medicines Market Share Analysis (%), By Radionuclide Type, 2018 & 2028
Figure 128: Global Therapeutic Nuclear Medicines Market Y-o-Y Analysis (%), By Radionuclide Type, 2018-2028
Figure 129: Global Therapeutic Nuclear Medicines Market Attractiveness Analysis by Radionuclide Type, 2018-2028
Figure 130: Global Therapeutic Nuclear Medicines Market Share Analysis (%), By Indication, 2018 & 2028
Figure 131: Global Therapeutic Nuclear Medicines Market Y-o-Y Analysis (%), By Indication, 2018-2028
Figure 132: Global Therapeutic Nuclear Medicines Market Attractiveness Analysis by Indication, 2018-2028
Figure 133: Global Therapeutic Nuclear Medicines Market Share Analysis (%), By End User, 2018 & 2028
Figure 134: Global Therapeutic Nuclear Medicines Market Y-o-Y Analysis (%), By End User, 2018-2028
Figure 135: Global Therapeutic Nuclear Medicines Market Attractiveness Analysis by End User, 2018-2028
Figure 136: Global Therapeutic Nuclear Medicines Market Value Analysis (US$ Mn), 2013-2017
Figure 137: Global Therapeutic Nuclear Medicines Market Value Forecast (US$ Mn), 2018-2028
Figure 138: Global Therapeutic Nuclear Medicines Market Absolute $ Opportunity, 2018 - 2028

 

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *